title: An update on enzalutamide in the treatment of prostate cancer.
abstract: Enzalutamide is an oral androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway. In the randomized phase III AFFIRM study, significant improvements in survival versus placebo were observed when enzalutamide was used as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) following prior treatment with docetaxel. Additional benefits included significant delay in time to first skeletal-related event, and improvement in several measures of pain and health-related quality of life. Treatment effects were consistent across all prespecified subgroups. The phase III PREVAIL study evaluated enzalutamide versus placebo in patients with mCRPC who had not received chemotherapy. Enzalutamide significantly decreased the risk of radiographic progression and death. There were also significant improvements in all secondary and prespecified exploratory endpoints, including delayed initiation of chemotherapy, reduction in risk of first skeletal-related event and a high percentage of patients with objective response compared with placebo. Enzalutamide was also studied in hormone naïve patients (as monotherapy) in a small, open-label phase II study in patients with prostate cancer who were eligible for androgen-deprivation therapy. A prostate-specific antigen (PSA) response, defined as ⩾80% decline in PSA level from baseline at week 25, was achieved in 92.5% of patients. Long-term follow up is ongoing. Despite differences between these three trials, enzalutamide displayed a favorable safety profile in all three patient populations. Similar rates of adverse events between the enzalutamide and placebo groups were observed in AFFIRM and PREVAIL, with fatigue, diarrhea, back pain and hot flashes being more common with enzalutamide than with placebo. Hypertension was reported at a higher rate in the enzalutamide group than in the placebo group in PREVAIL. Breast-related disorders associated with enzalutamide treatment were also reported in the Monotherapy trial. Few seizures were reported in any trial. Enzalutamide is being studied in several early disease state populations.
authors: Department of Urology and Urologic Oncology, Hannover Medical School (MHH), Carl Neuberg Str. 1, 30625 Hannover, Germany.
authors: Axel S
authors: AS
authors: Merseburger
authors: Astellas Global Medical Affairs, Inc., Northbrook, IL, USA.
authors: Gabriel P
authors: GP
authors: Haas
authors: Hannover Medical School (MHH), Hannover, Germany.
authors: Christoph-A
authors: CA
authors: von Klot
keywords: AFFIRM trial; PREVAIL trial; efficacy; enzalutamide; prostate cancer; safety
references: BJU Int. 2015 Mar;115(3):373-80
references: 24906049
references: Eur Urol. 2015 Jan;67(1):53-60
references: 24882673
references: Nat Rev Urol. 2014 Jul;11(7):366
references: 24960596
references: Ann Oncol. 2013 Jul;24(7):1802-7
references: 23585511
references: J Urol. 2013 Aug;190(2):429-38
references: 23665272
references: Oncologist. 1997;2(1):18-27
references: 10388026
references: Lancet Oncol. 2014 Sep;15(10):1147-56
references: 25104109
references: Adv Ther. 2014 Feb;31(2):234-41
references: 24442834
references: Eur Urol. 2015 Aug;68(2):317-24
references: 25108579
references: Eur Urol. 2014 Jan;65(1):30-6
references: 23849416
references: N Engl J Med. 2012 Sep 27;367(13):1187-97
references: 22894553
references: Am Soc Clin Oncol Educ Book. 2014;:117-31
references: 24857068
references: Science. 2009 May 8;324(5928):787-90
references: 19359544
references: Rev Urol. 2014;16(1):10-20
references: 24791151
references: Bonekey Rep. 2012 Jan 10;1:2
references: 23951414
references: Urologe A. 2013 Feb;52(2):219-25
references: 23160609
references: J Clin Oncol. 2004 Jul 1;22(13):2546-53
references: 15226323
references: Lancet Oncol. 2012 Oct;13(10):983-92
references: 22995653
references: Ann Oncol. 2013 Jul;24(7):1807-12
references: 23576708
references: Ann Oncol. 2014 Feb;25(2):429-34
references: 24478320
references: Eur Urol. 2014 Nov;66(5):815-25
references: 24647231
references: Eur Urol. 2015 Feb;67(2):223-30
references: 25171902
references: Scand J Urol. 2014 Jun;48(3):268-75
references: 24255983
references: Eur Urol. 2014 Jan;65(1):258-9
references: 24094574
references: N Engl J Med. 2014 Jul 31;371(5):424-33
references: 24881730
references: Int J Clin Pract. 2011 Nov;65(11):1180-92
references: 21995694
references: N Engl J Med. 2011 May 26;364(21):1995-2005
references: 21612468
references: World J Urol. 2014 Oct;32(5):1171-6
references: 24691670
references: Ther Adv Urol. 2013 Aug;5(4):201-10
references: 23904859
references: BJU Int. 2015 Jan;115(1):41-9
references: 25123978
references: Horm Cancer. 2014 Oct;5(5):265-73
references: 25048254
references: Cancer. 2014 Apr 1;120(7):968-75
references: 24382803
references: Lancet. 2010 Apr 24;375(9724):1437-46
references: 20398925
references: Oncologist. 2013;18(5):558-67
references: 23671006
references: Eur J Cancer. 2014 Jan;50(1):78-84
references: 24074764
references: Eur Urol. 2013 Aug;64(2):260-5
references: 23706522
references: J Clin Endocrinol Metab. 2014 Apr;99(4):1400-10
references: 24471567
references: Lancet Oncol. 2014 May;15(6):592-600
references: 24739897